← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Navidea Biopharmaceuticals, Inc.
Dublin, OH
$13,069,016
Total funding
9
Grants
Funding over time
peak $4.6M · FY2012–19$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$13,069,016 · 9
By mechanism
R44$12,522,178 · 7
R43$321,838 · 1
R41$225,000 · 1
Investigators at Navidea Biopharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries$1,500,000
R44 · FY2015 · CA
[18F]NAV4694 Imaging to Identify MCI Patients at Risk for Alzheimer's Dementia$1,257,437
R44 · FY2014 · AG
99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$1,125,665
R44 · FY2016 · AR
Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology$943,740
R44 · FY2015 · AG
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$939,552
R44 · FY2017 · CA
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$866,508
R44 · FY2017 · CA
[18F]NAV4694 Imaging to Identify MCI Patients at Risk for Alzheimer's Dementia$774,797
R44 · FY2015 · AG
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$688,135
R44 · FY2016 · CA
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$633,492
R44 · FY2016 · CA
Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology$629,160
R44 · FY2014 · AG
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$601,993
R44 · FY2018 · CA
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$538,135
R44 · FY2015 · CA
99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$374,335
R44 · FY2017 · AR
99mTc-Tilmanocept Targeting of Cardiovascular Plaque in HIV Subjects$321,838
R43 · FY2015 · HL
CC49/RIGS, a diagnostic radiopharmaceutical monoclonal antibody, for enhanced liv$315,217
R44 · FY2012 · CA
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$300,000
R44 · FY2015 · CA
Beta Amyloid Deposits Imaged with 18F-AZD4694 and Postmortem Histology$258,824
R44 · FY2013 · AG
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$232,464
R44 · FY2016 · CA
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques$225,000
R41 · FY2019 · HL
99mTc-Tilmanocept for Targeting Rheumatoid Arthritis (RA)-Driving Macrophages$224,993
R44 · FY2015 · AR